September 17, 2020
Bristol-Myers Squibb unit Celgene will permit Dr. Reddy's Laboratories Ltd. to sell a generic version of its cancer drug Revlimid on a limited basis after March 2022 and then an unlimited amount in 2026, under a deal unveiled Thursday in Celgene's New Jersey federal suits alleging the Indian drugmaker infringed its patents.
April 13, 2018
Celgene Corp. on Thursday tried to block Dr. Reddy's Laboratories Ltd. from making and selling a generic version of its blockbuster chemotherapy drug Revlimid, accusing the Indian drugmaker in New Jersey federal court of infringing five patents.